Protalix BioTherapeutics (PLX) Registration Filing summary

Management team and governance

• President and CEO is Dror Bashan, who also serves as principal executive officer and director.

• Eyal Rubin is Sr. Vice President, CFO, Treasurer, Secretary, and principal financial and accounting officer.

• Board includes Eliot Richard Forster, Ph.D. (Chair), Amos Bar Shalev, Shmuel Ben Zvi, Ph.D., Pol F. Boudes, M.D., Gwen A. Melincoff, and Aharon Schwartz, Ph.D.

Offering details and pricing

• Registration statement filed as a pre-effective amendment to Form S-3, allowing for securities to be offered from time to time after effectiveness.

• Securities may be offered on a delayed or continuous basis under Rule 415.

• Filing includes provisions for additional securities or classes under Rule 413(b).

Underwriters and syndicate

• Mayer Brown LLP listed as legal counsel for the offering.

• Form of underwriting agreement to be filed by amendment or as an exhibit to a current report on Form 8-K.